Literature DB >> 1419993

The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement.

M Falkeborn1, I Persson, H O Adami, R Bergström, E Eaker, H Lithell, R Mohsen, T Naessén.   

Abstract

OBJECTIVE: To determine the relative risk of developing a first acute myocardial infarction after treatment with oestrogens alone or oestrogen-progestogen combinations.
DESIGN: Prospective cohort study utilizing a prescription-based and record linkage system for a follow-up period from 1977 to 1983. Average individual observation time was 5.8 years.
SETTING: The entire female population of the Uppsala Health Care Region (1.4 million inhabitants), one-sixth of the total Swedish population.
SUBJECTS: 23,174 women aged 35 years and older, identified from pharmacy records as having been prescribed non-contraceptive oestrogens during 1977-1980. OUTCOMES: Admissions to hospitals for first acute myocardial infarctions.
RESULTS: Overall, 227 cases of a first acute myocardial infarction were observed as against 281:1 expected, RR = 0.81 (95% confidence limits 0.71 to 0.92). Women who were younger than 60 years at entry into the study and prescribed oestradiol compounds (1-2 mg) or conjugated oestrogens (0.625-1.25 mg) showed a significant 30% reduction of the relative risk (RR = 0.69, 0.54 to 0.86). Those prescribed a combined oestradiol-levonorgestrel brand also demonstrated a significantly lowered relative risk (RR = 0.53, 0.30 to 0.87). The risk estimates were near unity during the first year of follow-up but decreased during subsequent years. Exposure to the weak oestrogen oestriol did not alter the risk.
CONCLUSION: Hormonal replacement therapy with oestrogens alone, and maybe also when cyclically combined with progestogens, can reduce the risk of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419993     DOI: 10.1111/j.1471-0528.1992.tb14414.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  44 in total

Review 1.  The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?

Authors:  G Wells; D M Herrington
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 2.  Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.

Authors:  B Andersson
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 3.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 4.  What is the cardioprotective role of hormone replacement therapy?

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

5.  Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors:  B L Abramson
Journal:  CMAJ       Date:  2004-04-27       Impact factor: 8.262

Review 6.  Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  R H Foster; J A Balfour
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 7.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 8.  A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent.

Authors:  Howard N Hodis; Wendy J Mack
Journal:  Brain Res       Date:  2010-10-25       Impact factor: 3.252

9.  Congress on women's health Trudy Bush lecture 2014: new insights into sex Hormones and Cardiovascular disease.

Authors:  Virginia M Miller
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

Review 10.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.